The European Medicines Agency (EMA) has announced it is recommending granting a conditional marketing authorisation for Novavax’s COVID-19 vaccine Nuvaxovid (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age.
Nuvaxovid is a protein-based vaccine and is the fifth vaccine recommended in the EU for preventing COVID-19. This vaccine is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
Source: Cyprus News Agency